Advancements in Immunotherapy for Hepatocellula...

By João L. Carapinha

April 3, 2026

Immunotherapy hepatocellular carcinoma treatment has taken a significant step forward with positive high-level results from the EMERALD-3 Phase III trial. The addition of dual immunotherapy using AstraZeneca’s STRIDE regimen (Single Tremelimumab R...
Facilitating Reimbursement for Intravesical Gemcitabine in Bladder Cancer Tre...
100% Tariffs Impacting Pharmaceutical Manufacturing and National Security
Enhancing Obesity Treatment Pricing in South Africa Through Competitive Strat...
Real-World Evidence Integration into Cancer HTA: Scotland’s Success Story
Personalised Fertility Endometriosis Care in the UK
EU-India Pharmaceutical Trade: Opportunities and Challenges in Biopharmaceuti...
Nonclinical Safety Testing with Virtual Control Groups
Advancing Health Technology Assessment MENA: Insights and Implications for th...
Advancing Participatory Arts Health in Dutch Care Systems
Tarlatamab for Small Cell Lung Cancer Treatment
FDA Approves Once-Weekly Basal Insulin Awiqli® for Type 2 Diabetes Management
Inflation Reduction Act Impact on Clinical Trial Investment Trends